Zirkulierende Spiegel von ENA-78 in Abhängigkeit von Geschlecht und Nierenfunktion

Zusammenfassung

Epithelial neutrophil activating protein (ENA)-78 ist in subkutanem Fettgewebe adipöser Patienten höher exprimiert verglichen zu schlanken Probanden. In der vorliegenden Studie wurden die ENA-78-Spiegel in Abhängigkeit von Geschlecht und Nierenfunktion bei 120 Männern (n=62) und Frauen (n=58) untersucht. 60 dieser Patienten waren terminal niereninsuffizient, die anderen 60 Patienten wiesen eine glomeruläre Filtrationsrate >50 ml/min auf. ENA-78 wurde zu Parametern der Nierenfunktion, des Glukose- und Lipidstoffwechsels sowie zu Entzündungsmarkern korreliert. Die medianen ENA-78-Spiegel lagen bei Frauen höher (1410,15 pg/ml) als bei Männern (942,79 pg/ml) (p=0,002). Außerdem zeigten Hämodialysepatienten niedrigere (927,29 pg/ml) ENA-78-Werte als die Kontrollgruppe (1279,60 pg/ml) (p=0,006). In multivariaten Regressionsanalysen blieb die Abhängigkeit von zirkulierenden ENA78-Spiegeln vom Geschlecht bestehen (p=0,048). Weitere Studien sind erforderlich, um die physiologische Signifikanz unterschiedlicher ENA-78-Konzentrationen bei Männern und Frauen näher zu untersuchen.

Summary

Epithelial neutrophil activating protein (ENA)-78 is more highly expressed in subcutaneous adipose tissue of obese subjects as compared to lean controls. We investigated circulating ENA-78 levels in relation to gender and renal function. ENA-78 was determined in 120 men (n=62) and women (n=58). 60 of these patients had a glomerular filtration rate beyond 50 ml/min whereas the other patients were on chronic hemodialysis (CD; n=60). ENA-78 levels were assessed in relation to renal function, glucose and lipid metabolism, as well as inflammation. Median serum ENA-78 levels were significantly increased in women (1410.15 pg/ml) as compared with men (942.79 pg/ml) (p=0.002). Furthermore, median serum ENA-78 levels were significantly lower in CD patients (927.29 pg/ml) as compared with control subjects (1279.60 pg/ ml) (p=0.006). Moreover, gender predicted ENA-78 concentrations in multiple regression analysis (p=0.048). Further studies are needed to better elucidate the physiologic significance of circulating ENA-78 in both genders.

Schlüsselwörter

Adipokine - ENA-78 - Geschlecht - Nierenfunktion

Keywords

Adipokines - ENA-78 - gender - renal function

• Literatur

• 1 Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia 2003; 46: 1594-1603.
• 2 Horn R, Geldszus R, Potter E, von zur MA, Brabant G. Radioimmunoassay for the detection of leptin in human serum. Exp Clin Endocrinol Diabetes 1996; 104: 454-458.
• 3 Kapoor D, Clarke S, Stanworth R, Channer KS, Jones TH. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2007; 156: 595-602.
• 4 Kelesidis T, Kelesidis I, Chou S, Mantzoros CS. Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med 2010; 52: 93-100.
• 5 Kratzsch J, Berthold A, Lammert A, Reuter W, Keller E, Kiess W. A rapid, quantitative immunofunctional assay for measuring human leptin. Horm Res 2002; 57: 127-132.
• 6 Ma Z, Gingerich RL, Santiago JV, Klein S, Smith CH, Landt M. Radioimmunoassay of leptin in human plasma. Clin Chem 1996; 42: 942-946.
• 7 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
• 8 Merabet E, Dagogo-Jack S, Coyne DW, Klein S, Santiago JV, Hmiel SP, Landt M. Increased plasma leptin concentration in end-stage renal disease. J Clin Endocrinol Metab 1997; 82: 847-850.
• 9 Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, Matsuda M, Kondo H, Furuyama N, Kihara S, Nakamura T, Tochino Y, Funahashi T, Matsuzawa Y. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocytederived protein. Diabetes 2002; 51: 2734-2741.
• 10 Seeger J, Ziegelmeier M, Bachmann A, Lössner U, Kratzsch J, Blüher M, Stumvoll M, Fasshauer M. Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. J Clin Endocrinol Metab 2008; 93: 247-251.
• 11 Skopková M, Penesová A, Sell H, Rádiková Z, Vlcek M, Imrich R, Koska J, Ukropec J, Eckel J, Klimes I, Gasperíková D. Protein array reveals differentially expressed proteins in subcutaneous adipose tissue in obesity. Obesity (Silver Spring) 2007; 15: 2396-2406.
• 12 Trujillo ME, Scherer PE. Adipose tissue-derived factors: impact on health and disease. Endocr Rev 2006; 27: 762-778.
• 13 Tsou PL, Jiang YD, Chang CC, Wei JN, Sung FC, Lin CC, Chiang CC, Tai TY, Chuang LM. Sex-related differences between adiponectin and insulin resistance in schoolchildren. Diabetes Care 2004; 27: 308-313.
• 14 Walz A, Burgener R, Car B, Baggiolini M, Kunkel SL, Strieter RM. Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8. J Exp Med 1991; 174: 1355-1362.
• 15 Walz A, Strieter RM, Schnyder S. Neutrophil-activating peptide ENA-78. Adv Exp Med Biol 1993; 351: 129-137.
• 16 Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, TsuboyamaKasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 07: 941-946.
• 17 Ziegelmeier M, Bachmann A, Seeger J, Lossner U, Kratzsch J, Blüher M, Stumvoll M, Fasshauer M. Serum levels of adipokine retinol-binding protein-4 in relation to renal function. Diabetes Care 2007; 30: 2588-2592.
• 18 Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 134-141.